These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

431 related items for PubMed ID: 17175302

  • 1. Differential pharmacokinetic interaction of tacrolimus and cyclosporine on everolimus.
    Kovarik JM, Curtis JJ, Hricik DE, Pescovitz MD, Scantlebury V, Vasquez A.
    Transplant Proc; 2006 Dec; 38(10):3456-8. PubMed ID: 17175302
    [Abstract] [Full Text] [Related]

  • 2. A randomized long-term trial of tacrolimus and sirolimus versus tacrolimus and mycophenolate mofetil versus cyclosporine (NEORAL) and sirolimus in renal transplantation. I. Drug interactions and rejection at one year.
    Ciancio G, Burke GW, Gaynor JJ, Mattiazzi A, Roth D, Kupin W, Nicolas M, Ruiz P, Rosen A, Miller J.
    Transplantation; 2004 Jan 27; 77(2):244-51. PubMed ID: 14742989
    [Abstract] [Full Text] [Related]

  • 3. The pharmacokinetics of everolimus in de novo kidney transplant patients receiving tacrolimus: an analysis from the randomized ASSET study.
    Rostaing L, Christiaans MH, Kovarik JM, Pascual J.
    Ann Transplant; 2014 Jul 14; 19():337-45. PubMed ID: 25017487
    [Abstract] [Full Text] [Related]

  • 4. Everolimus therapeutic concentration range defined from a prospective trial with reduced-exposure cyclosporine in de novo kidney transplantation.
    Kovarik JM, Tedesco H, Pascual J, Civati G, Bizot MN, Geissler J, Schmidli H.
    Ther Drug Monit; 2004 Oct 14; 26(5):499-505. PubMed ID: 15385832
    [Abstract] [Full Text] [Related]

  • 5. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
    Dösch AO, Ehlermann P, Koch A, Remppis A, Katus HA, Dengler TJ.
    Clin Ther; 2006 Jun 14; 28(6):893-905. PubMed ID: 16860172
    [Abstract] [Full Text] [Related]

  • 6. Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: pharmacokinetics, exposure-response relationships, and influence on cyclosporine.
    Kovarik JM, Kahan BD, Kaplan B, Lorber M, Winkler M, Rouilly M, Gerbeau C, Cambon N, Boger R, Rordorf C, Everolimus Phase 2 Study Group.
    Clin Pharmacol Ther; 2001 Jan 14; 69(1):48-56. PubMed ID: 11180038
    [Abstract] [Full Text] [Related]

  • 7. Pharmacokinetics of mycophenolic acid in kidney transplant patients receiving sirolimus versus cyclosporine.
    El Haggan W, Ficheux M, Debruyne D, Rognant N, Lobbedez T, Allard C, Coquerel A, Ryckelynck JP, Hurault de Ligny B.
    Transplant Proc; 2005 Mar 14; 37(2):864-6. PubMed ID: 15848558
    [Abstract] [Full Text] [Related]

  • 8. Best single time points to predict the area-under-the-curve in long-term heart transplant patients taking mycophenolate mofetil in combination with cyclosporine or tacrolimus.
    Mardigyan V, Giannetti N, Cecere R, Besner JG, Cantarovich M.
    J Heart Lung Transplant; 2005 Oct 14; 24(10):1614-8. PubMed ID: 16210138
    [Abstract] [Full Text] [Related]

  • 9. Tacrolimus plus mycophenolate mofetil vs. cyclosporine plus everolimus in deceased donor kidney transplant recipients: three-yr results of a single-center prospective clinical trial.
    Favi E, Spagnoletti G, Salerno MP, Pedroso JA, Romagnoli J, Citterio F.
    Clin Transplant; 2013 Oct 14; 27(4):E359-67. PubMed ID: 23710603
    [Abstract] [Full Text] [Related]

  • 10. The pharmacokinetics of mycophenolate mofetil in renal transplant recipients receiving standard-dose or low-dose cyclosporine, low-dose tacrolimus or low-dose sirolimus: the Symphony pharmacokinetic substudy.
    Grinyó JM, Ekberg H, Mamelok RD, Oppenheimer F, Sánchez-Plumed J, Gentil MA, Hernandez D, Kuypers DR, Brunet M.
    Nephrol Dial Transplant; 2009 Jul 14; 24(7):2269-76. PubMed ID: 19357111
    [Abstract] [Full Text] [Related]

  • 11. Everolimus in de novo cardiac transplantation: pharmacokinetics, therapeutic range, and influence on cyclosporine exposure.
    Kovarik JM, Eisen H, Dorent R, Mancini D, Vigano M, Rouilly M, Hsu CH, Rordorf C.
    J Heart Lung Transplant; 2003 Oct 14; 22(10):1117-25. PubMed ID: 14550821
    [Abstract] [Full Text] [Related]

  • 12. Chronopharmacokinetics of mycophenolic acid and its glucuronide and acyl glucuronide metabolites in kidney transplant recipients converted from cyclosporine to everolimus.
    Tedesco-Silva H, Felipe CR, Slade A, Schmouder RL, Medina Pestana JO.
    Ther Drug Monit; 2012 Dec 14; 34(6):652-9. PubMed ID: 23131696
    [Abstract] [Full Text] [Related]

  • 13. Pharmacokinetics of everolimus when combined with cyclosporine in Japanese de novo renal transplant recipients.
    Uchida K, Hoshinaga K, Watarai Y, Goto N, Kusaka M, Sasaki H, Hirano M, A1202 PK Study Group.
    Transplant Proc; 2014 Jun 14; 46(5):1314-8. PubMed ID: 24935294
    [Abstract] [Full Text] [Related]

  • 14. Time-related clinical determinants of long-term tacrolimus pharmacokinetics in combination therapy with mycophenolic acid and corticosteroids: a prospective study in one hundred de novo renal transplant recipients.
    Kuypers DR, Claes K, Evenepoel P, Maes B, Coosemans W, Pirenne J, Vanrenterghem Y.
    Clin Pharmacokinet; 2004 Jun 14; 43(11):741-62. PubMed ID: 15301578
    [Abstract] [Full Text] [Related]

  • 15. Observational study with everolimus (Certican) in combination with low-dose cyclosporine in de novo heart transplant recipients.
    Lehmkuhl HB, Mai D, Dandel M, Knosalla C, Hiemann NE, Grauhan O, Huebler M, Pasic M, Weng Y, Meyer R, Rothenburger M, Hummel M, Hetzer R.
    J Heart Lung Transplant; 2007 Jul 14; 26(7):700-4. PubMed ID: 17613400
    [Abstract] [Full Text] [Related]

  • 16. Pharmacokinetic evaluation of MFF in combinations with tacrolimus and cyclosporine. Findings of C0 and AUC.
    Radzevičienė A, Stankevičius E, Saint-Marcoux F, Marquet P, Maslauskienë R, Kaduševičius E.
    Medicine (Baltimore); 2020 Mar 14; 99(12):e19441. PubMed ID: 32195940
    [Abstract] [Full Text] [Related]

  • 17. Cardiovascular risk profile in kidney transplant recipients treated with two immunosuppressive regimens: tacrolimus and mycophenolate mofetil versus everolimus and low-dose cyclosporine.
    Spagnoletti G, Citterio F, Favi E, Rossi E, Delreno F, De Santis I, Salerno MP, Gargiulo A, Castagneto M.
    Transplant Proc; 2009 May 14; 41(4):1175-7. PubMed ID: 19460509
    [Abstract] [Full Text] [Related]

  • 18. Heart transplantation under cyclosporine or tacrolimus combined with mycophenolate mofetil or everolimus.
    Wang SS, Chou NK, Chi NH, Wu IH, Chen YS, Yu HY, Huang SC, Wang CH, Ko WJ, Tsao CI, Sun CD.
    Transplant Proc; 2008 Oct 14; 40(8):2607-8. PubMed ID: 18929814
    [Abstract] [Full Text] [Related]

  • 19. Age-dependency of mycophenolate mofetil dosing in combination with tacrolimus after pediatric renal transplantation.
    Filler G, Foster J, Berard R, Mai I, Lepage N.
    Transplant Proc; 2004 Jun 14; 36(5):1327-31. PubMed ID: 15251324
    [Abstract] [Full Text] [Related]

  • 20. Combination of everolimus and tacrolimus in kidney transplant patients with intolerance to mycophenolate mofetil/mycophenolic acid.
    Balda S, Inza A, Odriozola N, Zárraga S, García-Erauskin G, Lampreabe I.
    Transplant Proc; 2009 Jun 14; 41(6):2095-8. PubMed ID: 19715841
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.